Adlai Nortye Ownership | Who Owns Adlai Nortye?
Adlai Nortye Ownership Summary
Adlai Nortye is owned by 166.19% institutional investors, 0.57% insiders. Eventide asset management is the largest institutional shareholder, holding 6.73% of ANL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 1.12% of its assets in Adlai Nortye shares.
ANL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Adlai Nortye | 166.19% | 0.57% | -66.77% |
| Sector | Healthcare Stocks | 247.07% | 12.15% | -159.22% |
| Industry | Biotech Stocks | 385.89% | 11.79% | -297.68% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Eventide asset management | 1.07M | 6.73% | $17.14M |
| Silverarc capital management | 216.62K | 1.36% | $3.47M |
| Ubs group | 159.19K | 1.00% | $2.55M |
| Affinity asset advisors | 153.85K | 0.97% | $2.46M |
| Marshall wace, llp | 76.21K | 0.48% | $1.22M |
| Toroso investments | 75.28K | 0.47% | $1.20M |
| Renaissance | 61.60K | 0.39% | $985.55K |
| Jpmorgan chase | 57.07K | 0.36% | $893.13K |
| Morgan stanley | 42.19K | 0.27% | $675.09K |
| State street | 36.20K | 0.23% | $579.20K |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Silverarc capital management | 216.62K | 0.41% | $3.47M |
| Act capital partners | 24.40K | 0.28% | $430.40K |
| Eventide asset management | 1.07M | 0.24% | $17.14M |
| Virtus investment advisers | 30.75K | 0.11% | $491.98K |
| Affinity asset advisors | 153.85K | 0.10% | $2.46M |
| Verition fund management | 34.00K | 0.00% | $543.94K |
| Toroso investments | 75.28K | 0.00% | $1.20M |
| Renaissance | 61.60K | 0.00% | $985.55K |
| China universal asset management | 1.60K | 0.00% | $25.04K |
| Marshall wace, llp | 76.21K | 0.00% | $1.22M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Eventide asset management | 1.07M | 0.24% | 352.54K |
| Silverarc capital management | 216.62K | 0.41% | 216.62K |
| Ubs group | 159.19K | 0.00% | 106.29K |
| Jpmorgan chase | 57.07K | - | 57.07K |
| Morgan stanley | 42.19K | - | 42.19K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Kalehua capital management | - | - | -226.41K |
| Price t rowe associates inc /md/ | - | - | -99.84K |
| Cantor fitzgerald, l. p. | - | - | -40.31K |
| Td asset management | - | - | -35.75K |
| Persistent asset partners | - | - | -33.73K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Silverarc capital management | 216.62K | 0.41% | 216.62K | $3.47M |
| Jpmorgan chase | 57.07K | - | 57.07K | $893.13K |
| Morgan stanley | 42.19K | - | 42.19K | $675.09K |
| State street | 36.20K | - | 36.20K | $579.20K |
| Walleye capital | 36.02K | 0.00% | 36.02K | $576.37K |
Sold Out
| Holder | Change |
|---|---|
| Bessemer group | -91.00 |
| Mirae asset global investments | -577.00 |
| Eversource wealth advisors | -4.79K |
| Smartharvest portfolios | -14.44K |
| Dymon asia capital (singapore) pte. | -15.00K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 42 | 61.54% | 26,460,735 | 128.37% | 166 | 3.14% | 31 | 24.00% | 7 | - |
| Mar 31, 2026 | 26 | 550.00% | 11,586,547 | 20659.96% | 108 | 39640.94% | 25 | 733.33% | - | -100.00% |
| Dec 31, 2025 | 4 | - | 55,812 | 243.18% | - | 2248.89% | 3 | 200.00% | 1 | -66.67% |
| Sep 30, 2025 | 4 | - | 16,263 | -72.75% | - | 48.52% | 1 | -75.00% | 3 | - |
| Jun 30, 2025 | 4 | - | 59,682 | 5.52% | - | 198.53% | 4 | 100.00% | - | -100.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 718.75K | 1.12% | 718.75K |
| Tema Oncology ETF | 103.06K | 0.16% | - |
| Virtus LifeSci Biotech Clinical Trls ETF | 30.75K | 0.05% | - |
| State Street® SPDR® S&P® EM Sm Cp ETF | 29.00K | 0.04% | - |
| Virtus Biotech Clinical Trials ETF | 25.89K | 0.04% | - |
| Fidelity Nasdaq Composite Index | 17.02K | 0.03% | - |
| Telescope Biotech Fund A FIL | 8.95K | 0.01% | - |
| State Street® SPDR® S&P® China ETF | 7.20K | 0.01% | - |
| ActivePassive International Equity ETF | 4.23K | 0.01% | - |
| JHVIT Health Sciences I | 1.71K | 0.00% | 1.71K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Ji Ping | - | Sell | $80.15K |
| Sep 30, 2026 | Ji Ping | - | Sell | $79.75K |
| Sep 29, 2026 | Ji Ping | - | Sell | $3.37K |
| Sep 22, 2026 | Ji Ping | - | Sell | $83.15K |
| Aug 26, 2026 | Ye Xiaofeng | CFO | Sell | $80.75K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2029 Q1 | - | - |
| 2026 Q2 | - | 1 |
| 2026 Q1 | - | - |
| 2024 Q3 | - | - |
| 2022 Q3 | - | - |
ANL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools